Zacks: OpGen Inc (NASDAQ:OPGN) Given $30.00 Consensus Price Target by Brokerages

OpGen Inc (NASDAQ:OPGN) has been given an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation.

Analysts have set a one year consensus target price of $30.00 for the company, according to Zacks. Zacks has also assigned OpGen an industry rank of 114 out of 255 based on the ratings given to related companies.

Separately, Zacks Investment Research cut OpGen from a “buy” rating to a “hold” rating in a research note on Wednesday, February 5th.

A number of institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC bought a new stake in shares of OpGen in the 4th quarter valued at $60,000. Renaissance Technologies LLC increased its position in shares of OpGen by 308.5% during the fourth quarter. Renaissance Technologies LLC now owns 68,188 shares of the medical research company’s stock worth $77,000 after buying an additional 51,494 shares during the period. Finally, Oxford Asset Management LLP bought a new position in OpGen during the fourth quarter worth $26,000. Hedge funds and other institutional investors own 0.32% of the company’s stock.

OPGN traded down $0.04 during midday trading on Friday, hitting $1.63. 202,968 shares of the company were exchanged. OpGen has a 1-year low of $0.92 and a 1-year high of $31.80. The firm’s 50 day moving average price is $1.56 and its 200-day moving average price is $2.75.

OpGen Company Profile

OpGen, Inc, a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms.

Recommended Story: What Are Cryptocurrencies?

Get a free copy of the Zacks research report on OpGen (OPGN)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit